ICAD’s high-performance, concurrent read, cancer detection and workflow solution for breast tomosynthesis delivers critical benefits to both radiologists and their patients. Axel Gräwingholt, Radiologie am Theater, Paderborn, Germany. I consider it to be one of the greatest tools in modern radiology,” said Dr. The product reduced my reading time by approximately 50 percent, allowing me to read these cases in nearly the same amount of time as 2D mammograms. “iCAD’s unique technology assists me in detecting more cancers, reassures me of my findings, and helps me concentrate on the essential work of a radiologist.
Icad nashua nh software#
“As tomosynthesis moves into the screening arena, our AI software provides important benefits to radiologists, their practices, and their patients.” We also understand that radiologists are concerned about the extra workload and long reading times of tomosynthesis cases in everyday practice and we are pleased to have created a meaningful solution to address this problem,” said Jeff Hoffmeister, MD, Vice President and Medical Director at iCAD. “As incidence rates of breast cancer continue to rise, we are proud to provide valuable technology that is proven to significantly improve detection rates while reducing unnecessary recalls resulting from false positives. In addition, when reading tomosynthesis cases with the solution, radiologists’ reading times were reduced by more than half (52.7 percent on average). The findings confirmed that the latest artificial intelligence (AI) software solution to support DBT increased improvements in both reader sensitivity (8.0 percent on average) and specificity (6.9 percent on average). 1 (4).NASHUA, N.H. and ATHENS, Greece-iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced outstanding clinical results of its new, leading-edge digital breast tomosynthesis (DBT) cancer detection software. The study demonstrated significant positive results for clinical performance and workflow efficiency. Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. It uses a proprietary miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.įor more information, visit and Contacts: The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. Additionally, ProFound AI for DBT improved radiologist sensitivity by 8 percent and reduced unnecessary patient recall rates by 7.2 percent. It offers clinically proven time-savings benefits to radiologists, including a reduction of reading time by 52.7 percent, thereby halving the amount of time it takes radiologists to read 3D mammography datasets. In 2018, ProFound AI for Digital Breast Tomosynthesis (DBT) became the first artificial intelligence (AI) software for DBT to be FDA-cleared it was also CE marked and Health Canada licensed that same year.
ProFound AI™ is a high-performing workflow solution for 2D and 3D mammography, or digital breast tomosynthesis (DBT), featuring the latest in deep-learning artificial intelligence.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, will present a corporate overview at the Guggenheim MedTech Disruptors Summit, taking place virtually on August 10-11, 2020.
0 kommentar(er)
